Is Spectrascience New Stock a Good Investment?
Spectrascience New Investment Advice | SCIE |
- Examine Spectrascience New's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Spectrascience New's leadership team and their track record. Good management can help Spectrascience New navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Spectrascience New's business and its evolving consumer preferences.
- Compare Spectrascience New's performance and market position to its competitors. Analyze how Spectrascience New is positioned in terms of product offerings, innovation, and market share.
- Check if Spectrascience New pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Spectrascience New's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Spectrascience New stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Spectrascience New is a good investment.
Not Rated
Examine Spectrascience New Stock
Researching Spectrascience New's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.01. Spectrascience New had not issued any dividends in recent years. The entity had 1:100 split on the 18th of November 2003.
To determine if Spectrascience New is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spectrascience New's research are outlined below:
| Spectrascience New generated a negative expected return over the last 90 days | |
| Spectrascience New has some characteristics of a very speculative penny stock | |
| Spectrascience New has high likelihood to experience some financial distress in the next 2 years | |
| Spectrascience New currently holds 6.38 M in liabilities. Spectrascience New has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Spectrascience New's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.15 K. Net Loss for the year was (4.47 M) with loss before overhead, payroll, taxes, and interest of (196.44 K). | |
| Spectrascience New currently holds about 27.88 K in cash with (1.51 M) of positive cash flow from operations. | |
| Spectrascience New has a frail financial position based on the latest SEC disclosures |
Spectrascience New Quarterly Long Term Debt |
|
Spectrascience New's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 K.Market Cap |
|
Spectrascience New's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (14.20) | (13.49) | |
| Return On Capital Employed | 0.23 | 0.25 | |
| Return On Assets | (3.71) | (3.52) | |
| Return On Equity | 0.38 | 0.40 |
Determining Spectrascience New's profitability involves analyzing its financial statements and using various financial metrics to determine if Spectrascience New is a good buy. For example, gross profit margin measures Spectrascience New's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spectrascience New's profitability and make more informed investment decisions.
Please note, the presentation of Spectrascience New's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spectrascience New's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spectrascience New's management manipulating its earnings.
Evaluate Spectrascience New's management efficiency
Spectrascience New has return on total asset (ROA) of (0.9247) % which means that it has lost $0.9247 on every $100 spent on assets. This is way below average. Spectrascience New's management efficiency ratios could be used to measure how well Spectrascience New manages its routine affairs as well as how well it operates its assets and liabilities. At present, Spectrascience New's Return On Equity is projected to slightly decrease based on the last few years of reporting. At present, Spectrascience New's Total Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.10, whereas Other Assets are forecasted to decline to about 88.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.02) | (0.02) | |
| Tangible Book Value Per Share | (0.02) | (0.02) | |
| Enterprise Value Over EBITDA | (3.16) | (3.01) | |
| Price Book Value Ratio | (0.13) | (0.12) | |
| Enterprise Value Multiple | (3.16) | (3.01) | |
| Price Fair Value | (0.13) | (0.12) | |
| Enterprise Value | 10 M | 9.5 M |
The operational strategies employed by Spectrascience New management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta (30.43) |
Basic technical analysis of Spectrascience Stock
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spectrascience New, as well as the relationship between them.Spectrascience New's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spectrascience New insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spectrascience New's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spectrascience New insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Miller Sheldon L over three months ago Acquisition by Miller Sheldon L of 100000 shares of Spectrascience New at 0.06 subject to Rule 16b-3 |
Spectrascience New's Outstanding Corporate Bonds
Spectrascience New issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spectrascience New uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spectrascience bonds can be classified according to their maturity, which is the date when Spectrascience New has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US84762LAX38 Corp BondUS84762LAX38 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Spectrascience Stock media impact
Far too much social signal, news, headlines, and media speculation about Spectrascience New that are available to investors today. That information is available publicly through Spectrascience media outlets and privately through word of mouth or via Spectrascience internal channels. However, regardless of the origin, that massive amount of Spectrascience data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spectrascience New news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spectrascience New relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spectrascience New's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spectrascience New alpha.
Spectrascience New Corporate Executives
Elected by the shareholders, the Spectrascience New's board of directors comprises two types of representatives: Spectrascience New inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrascience. The board's role is to monitor Spectrascience New's management team and ensure that shareholders' interests are well served. Spectrascience New's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrascience New's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lowell Giffhorn | CFO, Principal Accounting Officer and Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spectrascience New. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Spectrascience New's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.